Relmada THERAPEUTICS, Inc. (RLMD) intrinsic value & 10-year financials
Relmada THERAPEUTICS, Inc. (RLMD) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.10
- Market cap
- $122.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 417.9%
- Free cash flow (FY2025)
- —
RLMD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$57.4M | -$1.45 | — | — | — |
| FY2024 | — | -$80.0M | -$2.65 | — | — | — |
| FY2023 | — | -$98.8M | -$3.28 | — | — | — |
| FY2022 | — | -$157.0M | -$5.30 | — | — | — |
| FY2021 | — | -$125.8M | -$7.16 | — | — | — |
| FY2020 | — | -$59.5M | — | -$209.9M | — | — |
| FY2019 | — | -$15.0M | — | -$96.9M | — | -40.2% |
| FY2018 | — | -$9.0M | — | -$6.0M | — | 374.6% |
| FY2017 | $7.5K | -$6.3M | — | -$6.5M | -95880.4% | 1086.0% |
| FY2016 | — | -$3.0M | — | -$13.7M | — | 251.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
RELMADA THERAPEUTICS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
RELMADA THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -5.8% ROIC.
RELMADA THERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
RELMADA THERAPEUTICS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.